Surrozen, Inc. (NASDAQ:SRZN) Given Average Recommendation of “Moderate Buy” by Analysts

Surrozen, Inc. (NASDAQ:SRZN) has earned a consensus recommendation of “Moderate Buy” from the five research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $42.00.

Several research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research note on Tuesday, April 21st. Wall Street Zen raised shares of Surrozen from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. TD Cowen started coverage on shares of Surrozen in a research note on Tuesday, April 21st. They set a “buy” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $44.00 price objective (up from $36.00) on shares of Surrozen in a research note on Thursday, May 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $40.00 price objective on shares of Surrozen in a research note on Tuesday, March 24th.

Insider Buying and Selling at Surrozen

In other Surrozen news, major shareholder Tcg Crossover Gp Ii, Llc acquired 106,658 shares of the company’s stock in a transaction on Tuesday, March 24th. The shares were purchased at an average cost of $24.69 per share, with a total value of $2,633,386.02. Following the completion of the purchase, the insider owned 736,554 shares of the company’s stock, valued at approximately $18,185,518.26. This represents a 16.93% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Charles O. Williams sold 2,036 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $33.33, for a total transaction of $67,859.88. Following the completion of the transaction, the chief operating officer directly owned 16,571 shares in the company, valued at $552,311.43. This trade represents a 10.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 8,144 shares of company stock valued at $271,440 over the last ninety days. 31.74% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Empery Asset Management LP bought a new position in shares of Surrozen in the fourth quarter valued at $2,350,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Surrozen by 50.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock valued at $34,000 after purchasing an additional 500 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Surrozen by 22.6% during the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after purchasing an additional 5,702 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Surrozen during the fourth quarter valued at about $247,000. Finally, Citadel Advisors LLC lifted its position in shares of Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after purchasing an additional 3,424 shares in the last quarter. 66.57% of the stock is owned by institutional investors.

Surrozen Price Performance

Shares of NASDAQ SRZN opened at $23.39 on Wednesday. The firm has a market cap of $271.56 million, a PE ratio of -0.62 and a beta of 0.51. Surrozen has a 12-month low of $8.00 and a 12-month high of $35.00. The company’s fifty day simple moving average is $27.91 and its 200 day simple moving average is $24.71.

Surrozen (NASDAQ:SRZN) last issued its earnings results on Wednesday, May 6th. The company reported ($11.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($10.56). The company had revenue of $5.00 million for the quarter, compared to the consensus estimate of $4.00 million. Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 4,810.50%. On average, equities analysts predict that Surrozen will post -7.2 earnings per share for the current year.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.